Thinkbaby, owned by Topix Pharmaceuticals, is at the center of a major class action lawsuit, Cole v. Topix Pharmaceuticals Inc. Et Al (filed October 16, 2025, Case No. 1:25-cv-08577), challenging both the natural and sunblock claims in its baby sunscreen line. The lawsuit, filed in federal court, accuses Thinkbaby of misrepresenting its mineral sunscreens as all-natural and as being able to block all UV rays, allegedly violating FDA rules, FTC guidelines, and consumer protection statutes.
What the Lawsuit Alleges: Ingredients and Advertising Claims
The complaint details that Thinkbaby prominently markets its products as only natural, while actually including synthetics like cetyl dimethicone, caprylhydroxamic acid, and hexyl laurate. It is also not unreasonable for consumers to believe that a sunscreen product is free from unnatural ingredients, because many such products already exist on the market. The suit claims these synthetics, though regarded as safe, are not natural by any accepted industry…
or scientific definition—potentially misleading eco-conscious parents. On top of the natural claim, Thinkbaby’s use of the word sunblock is called out as more than just puffery.
In 2011, the FDA formally banned sunblock, waterproof, and sweatproof claims on sunscreen packaging, as no lotion or spray can literally block UV rays or guarantee all-day protection. The lawsuit echoes the FDA’s stance that consumers may wrongly “assume these products eliminate all sun risk.
The Consumer Experience: Premium Pricing and Reliance on Claims The lead plaintiff, a New York resident, noted multiple purchases of Thinkbaby sunscreen specifically due to beliefs that it was both effective and natural, with the expectation that her choices were best for her child’s health and sensitive skin.
The complaint argues that Thinkbaby profited from misleading all-natural sunblock language, encouraging purchasers to pay more for perceived safety and efficacy not backed by ingredient statements or real-world product behavior…
Discussion
0 Comments
No comments yet
Start the conversation
Share your take on this story and help shape the discussion.
Sign in to join the discussion.